Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
1500 participants
OBSERVATIONAL
2024-02-01
2035-01-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study in Patients With Myasthenia Gravis in China
NCT06700616
A Prospective Cohort Study of Myasthenia Gravis in China
NCT06006832
A Prospective Cohort Study Of Myasthenia Gravis
NCT04674605
Precision Diagnosis and Prospective Cohort Study for Myasthenia Gravis: Multicenter Analysis in China
NCT04535843
Construction of A Multimodal Digital Assessment Model for Myasthenia Gravis
NCT07146425
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Myasthenia gravis patients
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients themselves or their guardians can understand and sign the informed consent form.
To meet the eligibility criteria, at least one of the following additional criteria must be met:
* a. Positive Tensilon test;
* b. Decrease in compound muscle action potential by more than 10% with low-frequency repetitive nerve stimulation or widening of the "jitter" (the variability in time of the second action potential relative to the first) on single-fiber electromyography, with or without blocking;
* c. Positive antibodies: Serum testing positive for AChR antibodies, MuSK antibodies, or LRP4 antibodies.
Exclusion Criteria
* Patients with multiple organ dysfunction or in extremely critical condition, unable to complete relevant medical history collection or evaluation.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
China Alliance for Rare Diseases
UNKNOWN
National Center for Neurological Disorders (China)
UNKNOWN
China myasthenia gravis collaborating group (CMGCG)
UNKNOWN
Huashan Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Chongbo Zhao
Vice President
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Beijing Hospital
Beijing, Beijing Municipality, China
Xuanwu hospital, Capital medical university
Beijing, Beijing Municipality, China
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China
The First Affiliated Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China
The Third Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China
First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Xiangya hospital, Central south university
Changsha, Hunan, China
The First Hospital, Soochow University
Suzhou, Jiangsu, China
Affiliated Hospital of Xuzhou Medical University
Xuzhou, Jiangsu, China
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
The First Hospital, Jilin University
Changchun, Jilin, China
Huashan Hospital, Fudan University
Shanghai, Shanghai Municipality, China
Tangdu Hospital, The Air Force Medical University
Xi’an, Shanxi, China
West China Hospital, Sichuan University
Chengdu, Sichuan, China
Tianjin Medical University General Hospital
Tianjin, Tianjin Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Hua Zhang
Role: primary
Yuwei Da
Role: primary
Yuzhou Guan
Role: primary
Fei Xiao
Role: primary
Huiyu Feng
Role: primary
Wei Qiu
Role: primary
Bo Song
Role: primary
Huan Yang
Role: primary
Qun Xue
Role: primary
Yong Zhang
Role: primary
Daojun Hong
Role: primary
Hui Deng
Role: primary
Chongbo Zhao
Role: primary
Ting Chang
Role: primary
Hongyu Zhou
Role: primary
Chunsheng Yang
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022YFC3501303
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
82071410
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
82001335
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
2023M-022
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.